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Abstract
Background: Publications using the ALPPS (associating liver partition and portal vein ligation for a
staged hepatectomy) procedure have demonstrated a future liver remnant growth of 40–160% in only
6–9 days. The present study aimed to develop and describe the first large animal model of ALPPS that
can be used for future studies.
Methods: A total of 13 female domestic pigs underwent ALPPS stage 1 (portal vein division and
parenchymal transection) followed by ALPPS stage 2 (completion left-extended hepatectomy) 7 days
later. An abdominal computed tomography (CT) scan was performed immediately prior to ALPPS stage
1 surgery and again 7 days later to assess hypertrophy immediately prior to ALPPS stage 2 surgery.
Blood samples, as well as tissue analysis for Ki-67, were performed.
Results: On CT volumetric analysis, the mean size of the future liver remnant (FLR) prior to ALPPS
stage 1 was 21  2% and 40  6% prior to ALPPS stage 2. The median degree of growth was 75%
with a mean kinetic growth rate of 11% per day. Liver weights at autopsy correlated well with CT volu-
metric analysis (r = 0.87). There was no significant difference in mean lab values [asparate aminotrans-
ferase (AST), alanine aminotransferase (ALT), ammonia, International Normalized Ratio (INR) or
bilirubin] from baseline until immediately prior to ALPPS stage 2. Post ALPPS stage 2 there was a sig-
nificant increase in INR from baseline 1.1 to 1.6 (P = 0.012). No post-operative deaths secondary to
liver failure were observed.
Conclusion: The present study describes the first reproducible large animal model of the ALPPS proce-
dure. The degree of liver growth and the kinetic rate of growth were similar to that which has been dem-
onstrated in human publications. This model will be valuable as future laboratory studies are performed.
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Introduction
A liver resection remains the only potentially curative option
for many patients with primary or metastatic tumours of the
liver. Surgeons continue to expand what is defined as ‘resect-
able’ disease by performing increasingly extensive liver resec-
tions. In this setting, post-operative liver failure owing to an
insufficient liver remnant remains a significant concern, espe-
cially in patients that have received extensive chemotherapy.
Multiple reports describing the novel ALPPS procedure (asso-
ciating liver partition and portal vein ligation for a staged
hepatectomy) have demonstrated rapid growth in the future
liver remnant (FLR).1 Publications using the ALPPS procedure
have demonstrated a FLR growth of 40–160% in only 6–
9 days.1–11 This technique may allow for a liver resection in
patients with large or multiple liver tumours that would other-
wise be at high risk of liver failure owing to a small FLR.
Questions regarding the mechanism of profound growth
seen with ALPPS remain unanswered.12 It has been proposed
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and demonstrated that closure of the right portal branch by
ligation or embolization is followed by a reactive perfusion of
‘deportalized’ liver, from the contralateral one, through the int-
rahepatic branches and collaterals presents between the two
lobes.13,14 It is possible that the parenchymal division compo-
nent of ALPPS results in ligation of the collateral branches that
could account for the different rates of growth seen between
ALPPS and portal vein embolization (PVE). It has also been
suggested that that the deportalized liver may be responsible
for the release of circulating inflammatory or growth factors
that may account for the accelerated growth.15 Undoubtedly in
all settings, liver growth is multifactorial.
A large animal model is paramount to study the effects of
this new technique on the growth of the FLR. Such a model
would allow the understanding of molecular changes, blood
flow and growth characteristics that are associated with ALPPS.
Ideally this increased understanding would allow transition
into human clinical scenarios. The present study aimed to
develop and describe a large animal porcine model that could
be used for future research.
Materials and methods
This study was performed with the approval of the Mayo
Clinic Rochester Institutional Review Board. All animals
received humane care in compliance with the regulations of
the Institutional Animal Care and Use Committee at the Mayo
School of Graduate Medical Education. The number of study
animals for development of the model was determined by con-
sensus of the research team.
Procedure and peri-operative care
The first portion of the study involved six pigs in which the
techniques of ALPPS stage 1 were mastered, and initial liver
weights were determined after pig euthanasia. The second por-
tion of the study involved seven pigs in which ALPPS stage 1,
followed by a 7-day interval in which the FLR grew and then
subsequently ALPPS stage 2 were performed. Computed
tomography (CT) and surgical procedures were performed
under general anaesthesia. Post-operative liver failure was
defined according to a peak total bilirubin level > 7 mg/dl.16
The porcine liver is comprised of a right lateral (RL), right
medial (RM), left medial (LM), left lateral (LL) and caudate
lobes. The porcine vena cava is located intrahepatically on the
right side of the liver making a left extended hepatectomy the
resection procedure of choice.17,18 The caudate lobe and a por-
tion of the RL lobe have previously been shown to account for
15–20% of the liver.19 Therefore, it was planned for the cau-
date lobe and a portion of the RL lobe to be the FLR. ALPPS
stage 1 involved portal vein division (at the junction of the RL
and RM lobes) and parenchymal transection thus preserving
portal flow to the RL and caudate lobes and the arterial supply
and venous outflow to all portions of the liver (Fig. 1). This
was followed by ALPPS stage 2 (completion left-extended hep-
atectomy). Liver specimens were weighed upon removal at the
time of resection and all post-mortems.
Pre-operative and day 7 CT scans
An abdominal CT scan was performed immediately prior to AL-
PPS stage 1 surgery and again 7 days later to assess hypertrophy
immediately prior to ALPPS stage 2 surgery. Intravenous contrast
(Omnipaque 100 ml) was administered via the femoral vein dur-
ing CT scans for better definition of hepatic structures. Both arte-
rial and portal phases were obtained.
CT data were acquired and loaded onto 3-D volumetric soft-
ware (TeraRecon, Inc., Foster City, CA, USA). FLR (%) was calcu-
lated accordingly as FLR/total liver volume*100%. The degree of
growth/hypertrophy (DH) was defined as the percentage-point
difference between the FLR volume prior to ALPPS stage 1 and
FLR volume prior to ALPPS stage 2. Kinetic growth rate (KGR)
was calculated as both percentage growth per day [DH at the first
post-intervention volume assessment (%)/time elapsed since] as
well as the volume (cc) growth per day (FLR after intervention –
FLR prior to intervention/time elapsed).20
ALPPS surgery stage 1
Pigs do not tolerate > 500 ml of blood loss, and so a successful
surgical technique requires the risk of blood loss to be mini-
mized. The liver was mobilized by the division of the peritoneal
reflections to the diaphragm and a cholecystectomy was per-
Figure 1 Porcine liver anatomy showing right lateral (RL), right
medial (RM), left medial (LM), left lateral (LL) and caudate lobes.
During ALPPS stage 1: (a) site of transection to remove a portion
of the RL lobe is shown with a solid line, (b) second line shows the
level of portal vein ligation, (c) site of parenchymal transection
shown by a dashed line. Future liver remnant (FLR) is shown in
shaded and accounted for 15–20% of the liver volume
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formed. The adventitia was carefully dissected from the surface
of the portal vein at RL and the RM lobe junction. The hepatic
artery branches to the RL and RM lobes can be seen crossing
the anterior surface of the main portal vein at this location and
must be preserved. The portal vein was then encircled between
the takeoff of the branch to the RL and RM lobes. This was not
divided until the resection of the RL lobe was performed to
minimize bleeding once all of the portal flow is diverted to the
RL lobe and caudate. A parencymal resection was performed
between two rows of #1 Vicryl sutures placed along the resec-
tion line in the RL lobe. The parenchyma was then transected
using a CUSA (Cavitron Ultrasonic Surgical Aspirator) device
without inflow control. There are three large veins located at the
centre of the lobe and these were ligated using haemoclips.
The parenchyma was then divided so that there were no int-
rahepatic portal branches to the deportalized portion of the
liver (RM, LM and LL). The transection plane divided the
parenchyma over the anterior surface of the liver by the hepa-
tic veins extending this through the lateral part of the RM lobe
and in the groove between the RL and RM lobes making a tra-
jectory towards the left side of the caudate lobe. The inferior
vena cava and intraparenchymal hepatic veins have extremely
thin walls and are easily damaged. Once this was performed, a
right angle dissector was used to dissect bluntly behind the
hilar plate dropping it down. The hilar plate was then looped
with a vessel loop. A vessel loop was then also placed around
the isolated hepatic veins (Fig. 2). A sterile plastic sheet was
placed between the FLR and the deportalized portion of the
liver as well as under the midline wound to avoid adhesions at
the second stage surgery.
ALPPS surgery stage 2
The pigs formed a relatively large number of adhesions even in
the short 7-day period between surgeries and, therefore, care
must be taken in mobilizing the liver at the time of the second
operation. Prior to performing any significant mobilization,
the remaining portal structures in the left side of the hepa-
toduodenal ligament were divided. Care must be taken to
avoid injury to the bile duct as it courses posteriorly to the RL
lobe. The common bile duct was dissected from the other
structures in the hilar plate, dropping it down to avoid injury.
To divide the remaining liver, a vascular clamp was placed on
the staying side, and a 60-mm endovascular stapler with the
vascular load was used to divide the liver above it. A 3-0 Pro-
lene suture was then used to perform a running mattress
suture under the vascular clamp prior to removal. This tech-
nique was repeated until only the FLR remained (Fig. 3).
Light microscopy and evaluation of regeneration
For histomorphological evaluation, all liver specimens were
fixed in 4% phosphate-buffered paraformaldehyde. Liver speci-
mens were subsequently dehydrated and embedded in paraffin
wax to process sections at a thickness of 6 mm. The sections
were conventionally stained by hematoxylin and trichrome and
then examined using computer-assisted brightfield microscopy,
with 409 magnification. To evaluate the histological regenera-
tion of the remnant liver, the area of the periportal fields was
evaluated. Immunostainings were performed for the presence
of Ki67, a cellular marker for proliferation. The number of
Ki67 positive hepatocytes was determined by manual counting
in 20 random visual fields at 1009 magnification.
All statistical analyses were performed using STATA 12
(Stata Corp., College Station, TX, USA). Differences between
values were analysed using the unpaired t-test for continuous
variables and by the v2 test or continuity correction method
for categorical variables. Wilcoxon’s rank-sum was used for
variables that did not display a normal distribution or when
subject numbers were small. The degree of correlation was
Figure 2 Isolated hilum and hepatic veins at completion of ALPPS stage 1. All other connecting parenchyma have been divided
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assessed by Spearman’s rank correlation. All statistical tests
were two-sided, and differences were considered significant
when P < 0.05.
Results
A total of 13 female domestic pigs with a mean weight of
31  1 kg were used. Survival after ALPPS stage 1 was seen
with all pigs. Laboratory values are shown in Table 1.
On CT volumetric analysis, the mean size of the FLR prior
to ALPPS stage 1 was 174  33 cc. TLV had a mean size of
816  139 cc, with the FLR representing a mean 21  2% of
the TLV. Immediately (POD 7) prior to stage 2, the mean size
of the FLR and the TLV were 330  53 cc and 831  127 cc,
respectively. This resulted in FLR representing a mean of
40  6% of the total liver volume. The median degree of
growth was 76% (range 61–174%) (Fig. 4). The kinetic growth
rate was 23 cc/day (range 12–31 cc/day) in absolute growth, or
11%/day (9–24%/day) in percentage growth.
Liver weights at autopsy correlated well with CT volumetric
analysis (r = 0.87).
Histopathological Analysis of Liver Regeneration was per-
formed. The size of the portal fields increased significantly
between baseline (1.5  0.4 mm) and immediately prior to
ALPPS stage 2; after the 7-day time period (2.2  0.6 mm)
(P < 0.001) (Fig. 5). The number of Ki67 positive nuclei per
field (1009) also increased significantly between baseline
(12  3) and immediately prior to ALPPS stage 2 (35  7)
(P < 0.001).
Discussion
The present study is the first to describe a reproducible large
animal model of ALPPS. This study confirms that the signifi-
cant growth of the FLR after ALPPS stage 1 seen in humans
can also be demonstrated in pigs. This study demonstrates that
the increase in FLR volume seen on CT scan is associated with
an increase in the size of the portal tracts and Ki67 index on
histology.
The use of PVE to increase the size of FLR has become stan-
dard practice, with many centres demonstrating excellent
results.21,22 The ALPPS approach has emerged as a method to
induce rapid FLR growth. Unlike PVE, which enhances liver
growth 20–35% in 30–45 days, the ALPPS technique allows an
FLR growth of 40–160% in only 6–9 days.1–11 While the rapid
growth seen with the ALPPS technique has been well described,
questions regarding the mechanism of this profound growth
remain unanswered. Also, the initial volume evaluation is usu-
ally performed at 2–4 weeks after PVE, and the dynamic vol-
ume change during the very early phase after PVE remains
unclear. Therefore, actual dynamic volume changes after AL-
PPS and right PVE should be compared using animal mod-
els.23
While previous studies have described techniques of PVE in
pigs,13 the present study represents the first publication
describing a large animal model of the ALPPS procedure.
Development of this model is important to further characterize
the mechanism of the growth seen with ALPPS procedure as
well as to provide direct comparisons with PVE. Domestic
swine are commonly used in experimental surgery because of
the numerous similarities between porcine and human anat-
omy and physiology.16,23 Previous authors have recorded the
presence of macroscopic anastomosis between the branches of
Figure 3 Hypertrophied future liver remnant (FLR) [caudate and
portion of the right lateral (RL) lobe] after ALPPS Step 2 resection.
Vessel loop around protected bile duct
Table 1 Blood work prior to stage 1, prior to stage 2 and after stage 2
Prior to stage 1 Prior to stage 2 Post stage 2 P-value a versus b P-value b versus c
INR 1.1  0.1 1.1  0.1 1.6  0.1 NS 0.005
Bilirubin (mg/dl) 0.12  0.1 0.15  0.1 3.3  0.9 NS <0.001
AST (U/l) 27.6  6.5 29.2  7.0 30.5  1.5 NS NS
ALT (U/l) 46.6  3.9 45.5  4.0 50.0  2.0 NS 0.02
Alk P (U/l) 161.2  13.8 91.4  30.0 117.5  7.5 0.001 NS
NH3 (ug/dl) 68.5  20.3 95.0  40.4 53.0  5.0 NS 0.02
Hb (g/dl) 8.9  0.6 8.5  0.6 7.9  0.4 NS 0.04
ALT, alanine aminotransferase; AST, asparate aminotransferase; Alk P, alkaline phosphatase; Hb, haemoglobin.
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the portal vein, demonstrating intrahepatic collateralization.24, 25
Moreover, the size match with human organs makes results of
experimental surgical procedures more relevant as compared
with small animal models. Using a porcine model, CT volumet-
rics can be used to evaluate liver growth in a similar fashion to
what is performed with humans with some variability.
Recently, a study describing a murine animal model of
ALPPS was published by Schlegel et al.15 In that study a signif-
icant volume gain in the FLR was seen compared with portal
vein ligation or transection alone. Plasma obtained from mice
1 h after completion of ALPPS step 1, was also injected into
mice that had undergone portal vein ligation alone. This
induced comparable liver weight gain and hepatocyte prolifera-
tion, leading authors to propose that circulating factors play a
large role in the growth seen with ALPPS. These results are
very promising and highlight the importance of future research
into the mechanisms of liver growth.
The growth of the FLR seen with the current model
(74.5%) was similar to that described in the human litera-
ture.1–11 While standardized total liver volume (sTLV) has
been used in humans to calculate a standardized future liver
remnant volume (sFLR) no such equation has been validated
in a porcine model.26 This equation was designed to avoid
inclusion of tumour volume or dilated bile ducts in the set-
ting of cholangiocarcinoma when estimating TLV, neither of
which represented an issue in the present model. All pigs were
from a similar breeding lineage and had a similar starting
weight. Also, it was demonstrated that TLV showed only min-
imal variability at the time of the ALPPS stage 1 in the initial
six pigs.
On histological analysis, a significant increase in the size of
the portal fields and the number of Ki67 positive nuclei was
seen when compared with baseline. This highlights that the
volume increase of the FLR seen on CT volumetrics is associ-
ated with liver regeneration and is not simply caused by
congestion or another phenomenon.
Pigs in the 30-kg weight range are very sensitive to blood
loss. In the development of the current model, it was observed
that pigs were not able to tolerate a blood loss of greater than
500 cc. Transfusion was not used in the present study. The
techniques employed in the present study allowed completion
of both stages of the ALPPS model with less than 500 cc of
blood loss. Pigs in the present model also developed significant
adhesions in the 7-day interval between stage 1 and 2. While
adhesions are certainly an issue in human ALPPS, they are
even more profound in pigs. It is, therefore, important to stress
Baseline Immediately prior to ALPPS stage 2
Figure 4 Computed tomography (CT) scan showing baseline future liver remnant (FLR) and hypertrophied FLR
Baseline Immediately prior to ALPPS stage 2
7 days 
1.5±0.37 mm 2.2±0.59 mm P<0.001
Figure 5 Trichrome stain with 409 magnification showing an increase in the size of the portal fields from baseline to immediately prior to
ALPPS stage 2
HPB 2015, 17, 1130–1136 ª 2015 International Hepato-Pancreato-Biliary Association
1134 HPB
that completion of as much of the parenchymal transection
as possible in the first stage and the use of vessel loops to tag
critical structures should be employed.
Previous porcine liver models looking at liver failure after an
left extended liver resection (LL, LM, RM and portion of right
medial lobe) demonstrated liver failure leading to animal death
within 3 days after surgery in 65% of pigs.27 This was the same
extent of liver that was deportalized and ultimately resected in
ALPPS stage 2 in the present study. Despite the similar extent
of resection, none of the pigs demonstrated clinical or bio-
chemical signs of liver failure and no deaths were observed in
the 7 days between ALPPS stage 1 and stage 2. This highlights
the presumed auxiliary function of the deportalized liver as the
FLR is allowed to hypertrophy, as well as the functionality of
the FLR after ALPPS stage 2.
In conclusion, the present study describes the first reproduc-
ible large animal model of the ALPPS procedure and demon-
strates similar levels of growth to those seen in humans. This
model will be important to advance the understanding of the
mechanism of growth seen with this procedure.
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Additional Supporting Information may be found in the online version of this
article:
Figure S1. Experiment Timeline. Baseline CT scan and bloodwork were
performed followed by ALPPS Stage 1 and then a 7 day period to allow for
liver hypertrophy. This was followed by a second CT scan and then ALPPS
Stage 2. Pigs were then observed for a day, bloodwork was then drawn
and then pigs were euthanized
Figure S2. ALPPS stage 1. (a) Divided portal vein. (b) portal vein showing
openings for caudate (C) and RL lobe branches
Figure S3. Ki67 showing increase in the number of positive staining cells
from baseline to immediately prior to ALPPS stage 2. Positive staining for
Ki67 can be seen in brown
Table S1. Future liver remnant growth
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